menu
    • menu

    Company profile for Cerus Corporation

    NEW Drugs in Dev: 9
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company, deploying and supplying vital technologies and pathogen-protected blood components for blood centers, hospitals and ultimately patients who rely on safe blood. With the INTERCEPT Blood System, we are focused on protecting patients by delivering the full complement of reliable product...
    Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company, deploying and supplying vital technologies and pathogen-protected blood components for blood centers, hospitals and ultimately patients who rely on safe blood. With the INTERCEPT Blood System, we are focused on protecting patients by delivering the full complement of reliable products and expertise for transfusion medicine. Cerus develops and markets the INTERCEPT Blood System, and remains the only company in the blood transfusion space to earn both CE Mark and FDA approval.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cerus CorporationUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1220 Concord Avenue Concord, CA US 94520
    Telephone
    Telephone
    +1 925.288.6000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.cerus.com/Home/default.aspx
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cerus Announces Q4 2025 Revenue, Outlook
    Cerus Announces Q4 2025 Revenue, Outlook

    11 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260111066393/en/Cerus-Corporation-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2025-Product-Revenue-and-Provides-Outlook

    BUSINESSWIRE
    11 Jan 2026
    Share Share
    Cerus Announces IFC Abstracts & Workshop At 2025 AABB Meeting
    Cerus Announces IFC Abstracts & Workshop At 2025 AABB Meeting

    21 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251021249458/en/Cerus-Corporation-Announces-Abstracts-and-Industry-Workshop-on-IFC-at-the-2025-AABB-Annual-Meeting

    BUSINESSWIRE
    21 Oct 2025
    Share Share
    German Advisory Panel Recommends Safer Platelet Transfusions
    German Advisory Panel Recommends Safer Platelet Transfusions

    25 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250825692652/en/The-German-National-Blood-Advisory-Committee-Issues-Formal-Recommendation-for-Improving-the-Safety-of-Platelet-Transfusions

    BUSINESSWIRE
    25 Aug 2025
    Share Share
    Cerus Corporation Wins Grant to Improve Trauma Hemorrhage Care
    Cerus Corporation Wins Grant to Improve Trauma Hemorrhage Care

    21 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250721154296/en/Cerus-Corporation-Announces-Additional-Department-of-Defense-Award-to-Advance-Care-for-Major-Hemorrhage-in-Traumatic-Injury

    BUSINESSWIRE
    21 Jul 2025
    Share Share
    Cerus Updates on INTERCEPT Red Cell CE Mark Application
    Cerus Updates on INTERCEPT Red Cell CE Mark Application

    02 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250702232469/en/Cerus-Corporation-Provides-INTERCEPT-Red-Blood-Cell-CE-Mark-Application-Update

    BUSINESSWIRE
    02 Jul 2025
    Share Share
    Cerus Corporation Celebrates World Blood Donor Day 2025
    Cerus Corporation Celebrates World Blood Donor Day 2025

    13 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250613811092/en/Cerus-Corporation-Celebrates-World-Blood-Donor-Day-2025

    BUSINESSWIRE
    13 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search